Monday, October 3, 2022

< + > Auvelity, Newly Approved Drug For Major Depressive Disorder, To Face Payer Pricing And Reimbursement Challenges

Overcoming market access hurdles will be a challenge for Auvelity’s sponsor, Axsome Therapeutics. But, a favorable efficacy and safety profile will likely help to facilitate patient access.

No comments:

Post a Comment

< + > Sherpas Healthcare Solutions Relieves the Burden of Release of Information Requests

Health care organizations still have to handle thousands of patient record requests manually. In addition to individual records requested by...